Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes

    ... has been linked to increased sensitivity to the drug lenalidomide . Phase II and III clinical trials have demonstrated the efficacy of lenalidomide in improving clinical outcomes of patients with del(5q) MDS, ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine

    ... BACKGROUND: Lenalidomide and azanucleosides are commonly used to treat anemic patients ... agents (ESAs). Nonetheless, response rates to lenalidomide after azanucleosides treatment failure and their optimal ... in the Moffitt Cancer Center Clinical Database who received lenalidomide and azacitidine after ESA treatment failure. Rates of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?

    ... Lenalidomide induces in patients with myelodysplastic syndrome (MDS) and ... 50%, respectively. It is still unclear, however, how long lenalidomide treatment should be continued and whether or not the drug could ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    ... The impact of lenalidomide treatment on long-term outcomes of patients with lower risk ... multivariate methodology to analyse the influence of lenalidomide therapy on overall survival (OS) and acute myeloblastic leukaemia ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.

    ... BACKGROUND: Lenalidomide is approved for the treatment of anemia with ... death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes

    ... Introduction: Lenalidomide is an IMiDs? oral immunomodulatory compound developed for the ... syndromes (MDS). Long-term continuous treatment with lenalidomide beyond first response may be important to optimize responses and ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes

    ... (MDS) begins with assessment of karyotype and risk. Lenalidomide is approved for the treatment of patients who have ... only in the European Union. Mounting evidence suggests that lenalidomide is effective not only in reducing red blood cell (RBC) ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine are active in MDS patients, and may ... malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging results; however, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... double-blind study assessed the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS ... myelodysplastic syndromes (MDS). Patients received lenalidomide 10 mg/day days 1-21 (n = 69) or 5 mg/day days 1-28 (n = 69) of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide

    ... and decreased miR-145 and miR-146a expression. Lenalidomide is an immunomodulatory agent that selectively suppresses the ... of MDM2 with subsequent enhanced P53 degradation. Lenalidomide showed success in low- and intermediate-1-risk MDS as reported in ...

    Research Article last updated 07/20/2018 - 5:15pm.